Bone marrow dosimetry using 124I-PET

Journal of Nuclear Medicine

Volumn 53, Issue 4, 2012, Pages 615-621

  Schwartz, Jazmin ^a   Humm, John L ^a   Divgi, Chaitanya R ^b   Larson, Steven M ^a   O'Donoghue, Joseph A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Dosimetry; Marrow; PET

Indexed keywords

GIRENTUXIMAB I 124; MONOCLONAL ANTIBODY HUA33 I 124; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; BONE MARROW; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; HUMAN; ISOTOPE LABELING; KIDNEY CANCER; LUMBAR VERTEBRA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION ABSORPTION; RADIOIMMUNOTHERAPY; REACTION TIME;

ANTIBODIES, MONOCLONAL; BONE MARROW; FEMALE; HUMANS; INJECTIONS; IODINE RADIOISOTOPES; ISOTOPE LABELING; LUMBAR VERTEBRAE; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOMETRY; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84859400016     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096453     Document Type: Article

References (33)

1. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res. 1990;50:1039s-1042s.
2. Thomas SR, Maxon HR, Kereiakes JG, Saenger EL. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer. Radiology. 1977;122:731-737. (Pubitemid 8037648)
3. King M, Farncombe T. An overview of attenuation and scatter correction of planar and SPECT data for dosimetry studies. Cancer Biother Radiopharm. 2003;18:181-190. (Pubitemid 36538586)
4. DeNardo GL, Siantar CL, DeNardo SJ. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm. 2002;17:107-118. (Pubitemid 34208175)
5. Buchegger F, Chalandon Y, Pelegrin A, Hardman N, Mach JP. Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab9)2 fragments. J Nucl Med. 1991;32:1414-1421.
6. Johnson TK, Gonzalez R, Kasliwal RK, et al. Distribution of a breast-directed I-131-radiolabeled monoclonal antibody in blood and bone marrow: implications for radiation immunotherapy. Radiology. 1992;182:107-114.
7. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694. (Pubitemid 23115673)
8. Siegel J, Wessels B, Watson E, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjugates Radiopharm. 1990;3:213-234.
9. Sgouros G, Stabin M, Erdi Y, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys. 2000;27:2150-2164.
10. Wessels BW, Bolch WE, Bouchet LG, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med. 2004;45:1725-1733. (Pubitemid 47618483)
11. Williams LE, DeNardo GL, Meredith RF. Targeted radionuclide therapy. Med Phys. 2008;35:3062-3068. (Pubitemid 351904509)
12. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27:766-777. (Pubitemid 30456759)
13. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661-681. (Pubitemid 30207744)
14. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA. 2000;97:9226-9233. (Pubitemid 30627544)
15. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-310.
16. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173-1180.
17. 86Y with PET. Eur J Nucl Med Mol Imaging. 2011;38(suppl 1):S10-S18.
18. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557-1562. (Pubitemid 26321647)
19. Pentlow KS, Graham MC, Lambrecht RM, Cheung NK, Larson SM. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys. 1991;18:357-366.
20. 124I-cG250. J Nucl Med. 2011;52:535-540.
21. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med. 2011;52:1878-1885.
22. Mageras GA, McNamara S, Pham H, Xiong JP. Imaging for radiation treatment planning. In: Starkschall BCG, ed. Informatics in Radiation Oncology. Baton Rouge, LA: CRC Press. In press.
23. Humm JL, Lee J, O'Donoghue JA, et al. Changes in FDG tumor uptake during and after fractionated radiation therapy in a rodent tumor xenograft. Clin Positron Imaging. 1999;2:289-296.
24. Beddoe AH, Darley PJ, Spiers FW. Measurements of trabecular bone structure in man. Phys Med Biol. 1976;21:589-607.
25. Hough M, Johnson P, Rajon D, Jokisch D, Lee C, Bolch W. An image-based skeletal dosimetry model for the ICRP reference adult male: internal electron sources. Phys Med Biol. 2011;56:2309-2346.
26. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. (Pubitemid 43733519)
27. Hindorf C, Linden O, Tennvall J, Wingardh K, Strand SE. Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry. Cancer. 2002;94:1235-1239. (Pubitemid 34150884)
28. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal-cell carcinoma: a phase-I study of monoclonal antibody-G250. J Clin Oncol. 1993;11:738-750. (Pubitemid 23105683)
29. Welt S, Ritter G, Williams C, et al. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res. 2003;9:1338-1346. (Pubitemid 36418384)
30. Garinchesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Old LJ. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol. 1996;9:465-471. (Pubitemid 26323936)
31. Bolch WE, Patton PW, Rajon DA, Shah AP, Jokisch DW, Inglis BA. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton. J Nucl Med. 2002;43:97-108. (Pubitemid 34101196)
32. Jokisch DW, Rajon DA, Patton PW, Bolch WE. Methods for the inclusion of shallow marrow and adipose tissue in pathlength-based skeletal dosimetry. Phys Med Biol. 2011;56:2699-2713.
33. Shah AP, Bolch WE, Rajon DA, Patton PW, Jokisch DW. A paired-image radiation transport model for skeletal dosimetry. J Nucl Med. 2005;46:344-353. (Pubitemid 43073446)